ERBB2 and breast carcinoma: In the multivariate analysis, patients with TN were more likely to have a poorer OS and a higher breast cancer-specific mortality were showed compared with the HoR+/HER2- subgroup (OS, P = 0.01, adjusted hazard ratio (aHR) = 3.092; breast cancer-specific mortality, P = 0.012, aHR = 7.725).